<DOC>
	<DOCNO>NCT00003146</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy bone marrow peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow bone marrow peripheral stem cell transplantation treat patient multiple myeloma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I. Assess toxicity efficacy maximum tolerate dose busulfan , melphalan , thiotepa patient multiple myeloma . OUTLINE : This single arm , open label study . Peripheral blood stem cell ( PBSC ) collect cryopreserved , bone marrow harvest store , infusion day 0 . Patients receive oral busulfan every 6 hour day -8 , -7 , -6 . Melphalan administer continuous IV infusion 30 minute day -5 -4 . Thiotepa administer continuous IV infusion 2 hour day -3 -2 . Patients undergo PBSC bone marrow infusion 36-48 hour follow completion chemotherapy ( day 0 ) . Patients follow 100 day posttransplant every 3 month thereafter . PROJECTED ACCRUAL : 30 patient accrue .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose stage II/III multiple myeloma ( great normal beta2microglobulin ) meeting Salmon Durie criterion Stage I multiple myeloma must prior chemotherapy undergoing transplantation PATIENT CHARACTERISTICS : Age : 70 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2 mg/dL Renal : Creatinine clearance least 50 mg/min Cardiovascular : Left ventricular ejection fraction least 41 % Other : Not pregnant HIV negative PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>